Drug Trial Radar · NCT06181786
Study of NAV-240 in Healthy Volunteers
Last checked: Nov 20, 2026Latest source record: Jun 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
40
Actual
Start
Nov 22, 2023
Primary completion
Sep 4, 2024
Study completion Sep 4, 2024
Sponsor
- Lead sponsor
- Navigator Medicines, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- IMBiologics Corp.
- First posted
- Dec 26, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The primary purpose of this study is to evaluate the safety and tolerability of intravenous (IV) doses of NAV-240 in healthy volunteers.
Conditions
- Healthy
Interventions
NAV-240Drug
Intravenous administration of NAV-240
PlaceboDrug
Intravenous administration of matching placebo for NAV-240
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)Time frame: From the dose of study drug on Day 1 up to Day 71
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Syneos Health
Miami, Florida
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.